Novo Nordisk As Stock Three Year Return
| NOVA Stock | EUR 105.00 3.00 2.94% |
Novo Nordisk AS fundamentals help investors to digest information that contributes to Novo Nordisk's financial success or failures. It also enables traders to predict the movement of Novo Stock. The fundamental analysis module provides a way to measure Novo Nordisk's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Novo Nordisk stock.
Novo |
Novo Nordisk AS Company Three Year Return Analysis
Novo Nordisk's Tree Year Return shows the total annualized return generated from holding a fund or ETFs for the last three years. The return measure includes capital appreciation, losses, dividends paid, and all capital gains distributions. This return indicator is considered by many investors to be solid measures of fund mid-term performance.
More About Three Year Return | All Equity Analysis
Three Year Return | = | (Mean of Monthly Returns - 1) | X | 100% |
Although Three Year Fund Return indicator can give a sense of overall fund mid-term potential, it is recommended to compare fund performances against other similar funds, ETFs, or market benchmarks for the same 3 year interval.
| Competition |
Based on the latest financial disclosure, Novo Nordisk AS has a Three Year Return of 0.0%. This indicator is about the same for the Healthcare average (which is currently at 0.0) sector and about the same as Biotechnology (which currently averages 0.0) industry. This indicator is about the same for all Germany stocks average (which is currently at 0.0).
Did you try this?
Run Insider Screener Now
Insider ScreenerFind insiders across different sectors to evaluate their impact on performance |
| All Next | Launch Module |
Novo Fundamentals
| Return On Equity | 0.72 | |||
| Return On Asset | 0.22 | |||
| Profit Margin | 0.31 % | |||
| Operating Margin | 0.43 % | |||
| Current Valuation | 282.15 B | |||
| Shares Outstanding | 2.25 B | |||
| Shares Owned By Insiders | 0.01 % | |||
| Shares Owned By Institutions | 8.34 % | |||
| Price To Earning | 17.63 X | |||
| Price To Book | 27.50 X | |||
| Price To Sales | 1.68 X | |||
| Revenue | 176.95 B | |||
| Gross Profit | 148.51 B | |||
| EBITDA | 76.8 B | |||
| Net Income | 55.52 B | |||
| Cash And Equivalents | 1.64 B | |||
| Cash Per Share | 0.67 X | |||
| Total Debt | 20.77 B | |||
| Debt To Equity | 9.10 % | |||
| Current Ratio | 0.96 X | |||
| Book Value Per Share | 37.10 X | |||
| Cash Flow From Operations | 78.89 B | |||
| Earnings Per Share | 3.32 X | |||
| Price To Earnings To Growth | 2.00 X | |||
| Target Price | 116.88 | |||
| Number Of Employees | 54.39 K | |||
| Beta | 0.33 | |||
| Market Capitalization | 303.37 B | |||
| Total Asset | 241.26 B | |||
| Z Score | 8.4 | |||
| Annual Yield | 0.01 % | |||
| Five Year Return | 2.26 % | |||
| Net Asset | 241.26 B | |||
| Last Dividend Paid | 12.4 |
About Novo Nordisk Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Novo Nordisk AS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Novo Nordisk using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Novo Nordisk AS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Novo Stock
When determining whether Novo Nordisk AS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Novo Nordisk's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Novo Nordisk As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Novo Nordisk As Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novo Nordisk AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.